Physician profile
Eric A Wininger
NPI 1750489340
$8,229.71
in general payments reported to CMS, 2019-2025
36 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $1,671 · 2021: $2,508 · 2022: $1,527 · 2023: $16.34 · 2024: $190 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593 · Education: $32.27 · Gift: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.66 |
| Education | $32.27 |
| Gift | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,901.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,245.62 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.82 | 2019-2022 | |
| Lilly USA, LLC | $666.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $502.54 | 2019-2022 | |
| Abbott Laboratories | $489.27 | 2019-2022 | |
| Abbvie INC. | $388.18 | 2019-2025 | |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $342.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $255.18 | 2019-2021 | |
| Amarin Pharma, INC. | $216.91 | 2019-2021 | |
| Insulet Corporation | $194.47 | 2019-2025 | Omnipod |
| Genzyme Corporation | $177.00 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.94 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $109.52 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $76.57 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $63.35 | 2020-2022 | |
| Mannkind Corporation | $61.25 | 2020-2021 | |
| Medtronic, INC. | $57.31 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $46.27 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $46.04 | 2022-2025 | Strensiq |
| Beta Bionics, INC. | $26.09 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sekisui Diagnostics LLC | $25.00 | 2025 | |
| Acadia Pharmaceuticals INC | $17.67 | 2025 | Nuplazid |
| Sequel Med Tech, LLC | $16.14 | 2025 | Twiist |
| Companion Medical, INC. | $15.81 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.74 | 2025 | Austedo Xr |
| Medtronic Minimed, INC. | $14.19 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Becton, Dickinson and Company | $13.77 | 2020 | |
| Amgen INC. | $13.59 | 2024 | Tepezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.20 | 2022 | |
| Cequr Corporation | $12.82 | 2022 | |
| Shire North American Group INC | $12.32 | 2019 | |
| Ibsa Pharma INC. | $12.19 | 2019 | |
| Senseonics, Incorporated | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wininger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.